Active Ingredient History
All-trans retinoic acid (ATRA) also known as tretinoin is an active metabolite of vitamin A that has been demonstrated to inhibit the growth of cancer cells, some types of epithelial cells, and vascular smooth muscles. It is medication used for the treatment of acne. Tretinoin capsules are indicated for the induction of remission in patients with acute promyelocytic leukemia (APL), French-American-British (FAB) classification M3 (including the M3 variant), characterized by the presence of the t(15;17) translocation and/or the presence of the PML/RARα gene who are refractory to, or who have relapsed from, anthracycline chemotherapy, or for whom anthracycline based chemotherapy is contraindicated. Tretinoin is for the induction of remission only. For acne it is applied to the skin as a cream or ointment. For leukemia it is taken by mouth for up to three months. The exact mechanism of action of tretinoin in APL and acne treatment is unknown, but is known, that tretinoin activates three members of the retinoid acid (RAR) nuclear receptors (RARα, RARβ, and RARγ) which act to modify gene expression, subsequent protein synthesis, and epithelial cell growth and differentiation. It has not been established whether the clinical effects of tretinoin are mediated through activation of retinoic acid receptors, other mechanisms, or both. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Amyotrophic Lateral Sclerosis (Phase 1/Phase 2)
Anemia (Phase 1)
Astrocytoma (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoma, Adenoid Cystic (Phase 2)
Carcinoma, Basal Cell (Phase 3)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Squamous Cell (Phase 3)
Cholangitis, Sclerosing (Phase 2)
Cognitive Aging (Phase 2/Phase 3)
Collagen (Early Phase 1)
Colorectal Neoplasms (Phase 2)
Dermatitis, Phototoxic (Phase 3)
Dermatology (Phase 4)
Emphysema (Phase 2)
Glioma (Phase 2)
Healthy Volunteers (Phase 4)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 1)
Hyperpigmentation (Phase 4)
Immunologic Deficiency Syndromes (Phase 2)
Keratosis, Actinic (Phase 2)
Kidney Neoplasms (Phase 2)
Lentigo (Phase 2)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Monocytic, Acute (Phase 1)
Leukemia, Myeloid (Phase 3)
Leukemia, Myeloid, Acute (Phase 4)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Lung Diseases (Phase 2)
Lung Diseases, Obstructive (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoproliferative Disorders (Phase 2)
Melanoma (Phase 2)
Melanosis ()
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Neoplasms ()
Nerve Fibers (Phase 4)
Nerve Sheath Neoplasms (Phase 4)
Neuroblastoma (Phase 2)
Neutropenia (Phase 3)
Oligodendroglioma (Phase 2)
Pancreatic Neoplasms (Phase 2)
Pharmacokinetics (Early Phase 1)
Pigmentation Disorders (Phase 2)
Primary Myelofibrosis (Phase 1)
Prostatic Neoplasms (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2)
Purpura (Phase 3)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Rhytidoplasty (Phase 2)
Rosacea (Phase 3)
Skin Neoplasms (Phase 3)
Small Cell Lung Carcinoma (Phase 2)
Striae Distensae (Phase 4)
Therapeutics (Phase 4)
Tuberculosis (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue